Coupling Tumor Necrosis Factor-α with αv Integrin Ligands Improves its Antineoplastic Activity

Cancer Research

Volumn 64, Issue 2, 2004, Pages 565-571

  Curnis, Flavio ^a   Gasparri, Anna ^a   Sacchi, Angelina ^a   Longhi, Renato ^b   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLCYSTEINYLASPARTYLCYSTEINYLARGINYLGLYCYLASPARTYLCYSTEINYLPHENYLALANYLC YSTEINYLGLYCINE; ANGIOGENIC FACTOR; ARGININE; ARGINYLGLYCYLASPARTIC ACID; ASPARTIC ACID; CD51 ANTIGEN; GLYCINE; INTERCELLULAR ADHESION MOLECULE 1; MELPHALAN; MICROSOMAL AMINOPEPTIDASE; POLYPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLYSIS; DNA RECOMBINATION; DRUG BINDING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FLOW CYTOMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; INTEGRIN ALPHAV; LYMPHOMA; MICE; MICE, INBRED C57BL; NECROSIS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642434101     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1753     Document Type: Article

References (46)

1. Fiers, W. Biologic therapy with TNF: preclinical studies. In: V. De Vita, S, Hellman, and S. Rosenberg (eds.), Biologic Therapy of Cancer: Principles and Practice, pp. 295-327. Philadelphia: J. B. Lippincott Company, 1995.
2. Fraker, D. L., Alexander, H. R., and Pass, H. I. Biologic therapy with TNF: systemic administration and isolation-perfusion. In: V. De Vita, S. Hellman, and S. Rosenberg (eds.), Biologic Therapy of Cancer: Principles and Practice, pp. 329-345. Philadelphia: J. B. Lippincott Company, 1995.
3. Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52-60, 1992.
4. Eggermont, A. M., Schraffordt Koops, H., Lienard, D., Kroon, B. B., van Geel, A. N., Hoekstra, H. J., and Lejeune, F. J. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol., 14: 2653-2665, 1996.
5. Fraker, D. L., Alexander, H. R., Andrich, M., and Rosenberg, S. A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon γ: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol., 14: 479-489, 1996.
6. Alexander, H. R., Jr., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T., and Rosenberg, S. A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol., 16: 1479-1489, 1998.
7. Gasparri, A., Moro, M., Curnis, F., Sacchi, A., Pagano, S., Veglia, F., Casorati, G., Siccardi, A. G., Dellabona, P., and Corti, A. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor α in mouse models. Cancer Res., 59: 2917-2923, 1999.
8. Nawroth, P., Handley, D., Matsueda, G., De Waal, R., Gerlach, H., Blohm, D., and Stern, D. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med., 168: 637-647, 1988.
9. Nawroth, P. P., and Stern, D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med., 163: 740-745, 1986.
10. Palladino, M. A., Jr., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., Deleo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., Liggitt, D., and Patton, J. S. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol., 138: 4023-4032, 1987.
11. Clauss, M., Murray, J. C., Vianna, M., de Waal, R., Thurston, G., Nawroth, P., Gerlach, H., Bach, R., Familletti, P. C., and Stern, D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J. Biol. Chem., 265: 7078-7083, 1990.
12. Kilbourn, R. G., Gross, S. S., Jubran, A., Adams, J., Griffith, O. W., Levi, R., and Lodato, R. F. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl. Acad. Sci. USA, 87: 3629-3632, 1990.
13. Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (Wash. DC), 279: 377-380, 1998.
14. Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., and Pasqualini, R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med., 5: 1032-1038, 1999.
15. Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol., 18: 1185-1190, 2000.
16. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 60: 722-727, 2000.
17. v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 15: 542-546, 1997.
18. Colombo, G., Curnis, F., De Mori, G. M., Gasparri, A., Longoni, C., Sacchi, A., Longhi, R., and Corti, A. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem., 277: 47891-47897, 2002.
19. Ljunggren, H. G., and Karre, K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med., 162: 1745-1759, 1985.
20. Moro, M., Pelagi, M., Fulci, G., Paganelli, G., Dellabona, P., Casorati, G., Siccardi, A. G., and Corti, A. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor α. Cancer Res., 57: 1922-1928, 1997.
21. Edgell, C. J., McDonald, C. C., and Graham, J. B. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. USA, 80: 3734-3737, 1983.
22. Corti, A., Poiesi, C., Merli, S., and Cassani, G. Tumor necrosis factor (TNF) α quantification by ELISA and bioassay: effects of TNF α-soluble TNF receptor (p55) complex dissociation during assay incubations. J. Immunol. Methods, 177: 191-198, 1994.
23. Ratti, S., Curnis, F., Longhi, R., Colombo, B., Gasparri, A., Magni, F., Manera, E., Metz-Boutigue, M. H., and Corti, A. Structure-activity relationships of chromogranin A in cell adhesion. Identification and characterization of an adhesion site for fibroblasts and smooth muscle cells. J. Biol. Chem., 275: 29257-29263, 2000.
24. Pelagi, M., Curnis, F., Colombo, B., Rovere, P., Sacchi, A., Manfredi, A. A., and Corti, A. Caspase inhibition reveals functional cooperation between p55- and p75-TNF receptors in cell necrosis. Eur. Cytokine Netw., 11: 580-588, 2000.
25. Smith, R. A., and Baglioni, C. The active form of tumor necrosis factor is a trimer. J. Biol. Chem., 262: 6951-6954, 1987.
26. Koivunen, E., Wang, B., and Ruoslahti, E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Bio/Technology, 13: 265-270, 1995.
27. Doukas, J., and Pober, J. S. IFN-γ enhances endothelial activation induced by tumor necrosis factor but not IL-1. J. Immunol., 145: 1727-1733, 1990.
28. Curnis, F., Sacchi, A., and Corti, A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Investig., 110: 475-482, 2002.
29. Pennica, D., Lam, V. T., Mize, N. K., Weber, R. F., Lewis, M., Fendly, B. M., Lipari, M. T., and Goeddel, D. V. Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation. J. Biol. Chem., 267: 21172-21178, 1992.
30. Hohmann, H. P., Brockhaus, M., Baeuerle, P. A., Remy, R., Kolbeck, R., and van Loon, A. P. Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-κ B. TNF α is not needed for induction of a biological effect via TNF receptors. J. Biol. Chem., 265: 22409-22417, 1990.
31. Loetscher, H., Stueber, D., Banner, D., Mackay, F., and Lesslauer, W. Human tumor necrosis factor α (TNF α) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J. Biol. Chem., 268: 26350-26357, 1993.
32. Grell, M., Scheurich, P., Meager, A., and Pfizenmaier, K. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res., 12: 143-148, 1993.
33. Smith, C. A., Davis, T., Anderson, D., Solam, L., Beckmann, M. P., Jerzy, R., Dower, S. K., Cosman, D., and Goodwin, R. G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (Wash. DC), 248: 1019-1023, 1990.
34. Schall, T. J., Lewis, M., Koller, K. J., Lee, A., Rice, G. C., Wong, G. H., Gatanaga, T., Granger, G. A., Lentz, R., Raab, H., et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell, 61: 361-370, 1990.
35. 125I-labeled recombinant human tumor necrosis factor to cell surface receptors. J. Biochem. (Tokyo), 100: 531-541, 1986.
36. Aiyer, R. A., and Aggarwal, B. B. Characterization of receptors for recombinant human tumor necrosis factor-α from human placental membranes. Lymphokine Res., 9: 333-344, 1990.
37. Adamson, G. M., and Billings, R. E. Tumor necrosis factor: receptor binding and expression of receptors in cultured mouse hepatocytes. J. Pharmacol. Exp. Ther., 269: 367-373, 1994.
38. Kobayashi, H., Fukata, J., Murakami, N., Usui, T., Ebisui, O., Muro, S., Hanaoka, I., Inoue, K., Imura, H., and Nakao, K. Tumor necrosis factor receptors in the pituitary cells. Brain Res., 758: 45-50, 1997.
39. Ameloot, P., Takahashi, N., Everaerdt, B., Hostens, J., Eugster, H. P., Fiers, W., and Brouckaert, P. Bioavailability of recombinant tumor necrosis factor determines its lethality in mice. Eur. J. Immunol., 32: 2759-2765, 2002.
40. Lejeune, F. J. High dose recombinant tumour necrosis factor (rTNF α) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur. J. Cancer, 31A: 1009-1016, 1995.
41. Rossi, C. R., Foletto, M., Di Filippo, F., Vaglini, M., Anza, M., Azzarelli, A., Pilati, P., Mocellin, S., and Lise, M. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer (Phila.), 86: 1742-1749, 1999.
42. van der Veen, A. H., de Wilt, J. H., Eggermont, A. M., van Tiel, S. T., Seynhaeve, A. L., and ten Hagen, T. L. TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br. J. Cancer, 82: 973-980, 2000.
43. Kristensen, C. A., Nozue, M., Boucher, Y., and Jain, R. K. Reduction of interstitial fluid pressure after TNF-α treatment of three human melanoma xenografts. Br. J. Cancer, 74: 533-536, 1996.
44. Suzuki, S., Ohta, S., Takashio, K., Nitanai, H., and Hashimoto, Y. Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-α in mice. Int. J. Cancer, 46: 1095-1100, 1990.
45. de Wilt, J. H., ten Hagen, T. L., de Boeck, G., van Tiel, S. T., de Bruijn, E. A., and Eggermont, A. M. Tumour necrosis factor α increases melphalan concentration in tumour tissue after isolated limb perfusion. Br. J. Cancer, 82: 1000-1003, 2000.
46. Curnis, F., Arrigoni, G., Sacchi, A., Fischetti, L., Arap, W., Pasqualini, R., and Corti, A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia and myeloid cells. Cancer Res., 62: 867-874, 2002.